Acute antibody-mediated rejection following heart transplantation

W. E. Uber; S. E. Self; A. B. Van Bakel; N. L. Pereira

doi:10.1111/j.1600-6143.2007.01900.x

Acute antibody-mediated rejection following heart transplantation

W. E. Uber, S. E. Self, A. B. Van Bakel, N. L. Pereira

Cardiovascular Medicine

Research output: Contribution to journal › Short survey › peer-review

76 Scopus citations

Abstract

Acute antibody-mediated rejection (AMR) in heart transplantation is often associated with hemodynamic compromise, and is associated with increased mortality and development of accelerated transplant coronary artery disease (TCAD). The diagnosis of AMR has historically been controversial and outcomes with aggressive immunosuppressive therapy including plasmapheresis and cyclophosphamide are poor. Advances in diagnostic techniques like the demonstration of immunopathologic evidence for antibody-mediated rejection by deposition of the complement split product C4d in tissue and detection of anti-HLA antibodies by flow cytometry will assist in further characterizing AMR. Immunosuppression targeting B-lymphocytes and use of m-TOR inhibitors to alter the predilection to develop TCAD and improve survival in AMR remains to be proven.

Original language	English (US)
Pages (from-to)	2064-2074
Number of pages	11
Journal	American Journal of Transplantation
Volume	7
Issue number	9
DOIs	https://doi.org/10.1111/j.1600-6143.2007.01900.x
State	Published - Sep 2007

Keywords

Antibody-mediated rejection
Complications
Diagnosis
Heart transplantation
Immunosuppressive therapy
Transplant coronary artery disease

ASJC Scopus subject areas

Immunology and Allergy
Transplantation
Pharmacology (medical)

Access to Document

10.1111/j.1600-6143.2007.01900.x

Cite this

@article{7223778f4e26409b905e8d2b2857a0c8,

title = "Acute antibody-mediated rejection following heart transplantation",

abstract = "Acute antibody-mediated rejection (AMR) in heart transplantation is often associated with hemodynamic compromise, and is associated with increased mortality and development of accelerated transplant coronary artery disease (TCAD). The diagnosis of AMR has historically been controversial and outcomes with aggressive immunosuppressive therapy including plasmapheresis and cyclophosphamide are poor. Advances in diagnostic techniques like the demonstration of immunopathologic evidence for antibody-mediated rejection by deposition of the complement split product C4d in tissue and detection of anti-HLA antibodies by flow cytometry will assist in further characterizing AMR. Immunosuppression targeting B-lymphocytes and use of m-TOR inhibitors to alter the predilection to develop TCAD and improve survival in AMR remains to be proven.",

keywords = "Antibody-mediated rejection, Complications, Diagnosis, Heart transplantation, Immunosuppressive therapy, Transplant coronary artery disease",

author = "Uber, {W. E.} and Self, {S. E.} and {Van Bakel}, {A. B.} and Pereira, {N. L.}",

year = "2007",

month = sep,

doi = "10.1111/j.1600-6143.2007.01900.x",

language = "English (US)",

volume = "7",

pages = "2064--2074",

journal = "American Journal of Transplantation",

issn = "1600-6135",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Acute antibody-mediated rejection following heart transplantation

AU - Uber, W. E.

AU - Self, S. E.

AU - Van Bakel, A. B.

AU - Pereira, N. L.

PY - 2007/9

Y1 - 2007/9

N2 - Acute antibody-mediated rejection (AMR) in heart transplantation is often associated with hemodynamic compromise, and is associated with increased mortality and development of accelerated transplant coronary artery disease (TCAD). The diagnosis of AMR has historically been controversial and outcomes with aggressive immunosuppressive therapy including plasmapheresis and cyclophosphamide are poor. Advances in diagnostic techniques like the demonstration of immunopathologic evidence for antibody-mediated rejection by deposition of the complement split product C4d in tissue and detection of anti-HLA antibodies by flow cytometry will assist in further characterizing AMR. Immunosuppression targeting B-lymphocytes and use of m-TOR inhibitors to alter the predilection to develop TCAD and improve survival in AMR remains to be proven.

AB - Acute antibody-mediated rejection (AMR) in heart transplantation is often associated with hemodynamic compromise, and is associated with increased mortality and development of accelerated transplant coronary artery disease (TCAD). The diagnosis of AMR has historically been controversial and outcomes with aggressive immunosuppressive therapy including plasmapheresis and cyclophosphamide are poor. Advances in diagnostic techniques like the demonstration of immunopathologic evidence for antibody-mediated rejection by deposition of the complement split product C4d in tissue and detection of anti-HLA antibodies by flow cytometry will assist in further characterizing AMR. Immunosuppression targeting B-lymphocytes and use of m-TOR inhibitors to alter the predilection to develop TCAD and improve survival in AMR remains to be proven.

KW - Antibody-mediated rejection

KW - Complications

KW - Diagnosis

KW - Heart transplantation

KW - Immunosuppressive therapy

KW - Transplant coronary artery disease

UR - http://www.scopus.com/inward/record.url?scp=34547850860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547850860&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2007.01900.x

DO - 10.1111/j.1600-6143.2007.01900.x

M3 - Short survey

C2 - 17614978

AN - SCOPUS:34547850860

SN - 1600-6135

VL - 7

SP - 2064

EP - 2074

JO - American Journal of Transplantation

JF - American Journal of Transplantation

IS - 9

ER -

Acute antibody-mediated rejection following heart transplantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this